Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 483421 - 483440 out of 495964 entries
Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
---|---|---|---|---|---|---|---|---|
USA | (M05BA08) zoledronic acid (adm: P, course dose) | RECLAST 5MG/100ML INJ | 1X100ML | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | Sandoz,Inc. |
USA | (M05BA08) zoledronic acid (adm: P, course dose) | ZOLEDRONIC ACID INJ,4MG/100ML | 100ML | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | SagentPharmaceuticals |
USA | (M05BB03) alendronic acid and colecalciferol (adm: O, refers to alendronic acid) | FOSAMAX PLUS D | 4 | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | OrganonLLC |
USA | (M05BB03) alendronic acid and colecalciferol (adm: O, refers to alendronic acid) | FOSAMAX PLUS D | 4 | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | OrganonLLC |
USA | (M05BB03) alendronic acid and colecalciferol (adm: O, refers to alendronic acid) | FOSAMAX PLUS D | 4 | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | OrganonLLC |
USA | (M05BB03) alendronic acid and colecalciferol (adm: O, refers to alendronic acid) | FOSAMAX PLUS D | 4 | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | OrganonLLC |
USA | (M05BX04) denosumab (adm: P) | XGEVA 120MG/1.7ML INJ | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | AmgenUSA,Inc. |
USA | (M05BX04) denosumab (adm: P) | XGEVA 120MG/1.7ML INJ | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | AmgenUSA,Inc. |
USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
USA | (M05BX05) burosumab (adm: P) | CRYSVITA 10MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
USA | (M05BX05) burosumab (adm: P) | CRYSVITA 10MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
USA | (M05BX05) burosumab (adm: P) | CRYSVITA 20MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
USA | (M05BX05) burosumab (adm: P) | CRYSVITA 20MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
USA | (M05BX05) burosumab (adm: P) | CRYSVITA 30MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
USA | (M05BX05) burosumab (adm: P) | CRYSVITA 30MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
USA | (M05BX06) romosozumab (adm: P) | EVENITY 105MG/1.17ML INJ,SOLN SYR | 2X1.17ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis | AmgenUSA,Inc. |
USA | (M05BX06) romosozumab (adm: P) | EVENITY 105MG/1.17ML INJ,SOLN SYR | 2X1.17ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis | AmgenUSA,Inc. |